


Chemicals & Petrochemicals | Small Cap
Tatva Chintan Pharma Chem Ltd demonstrates a mixed financial performance. The company shows excellent solvency and coverage ratios, indicating it has very little debt and strong ability to meet its interest and dividend obligations. Profitability is also a strong point, characterized by high gross profit, return on capital employed, and operating and net margins. However, the company struggles with efficiency, growth, and financial ratios. Its turnover ratios are low, suggesting challenges in utilizing assets effectively, and growth metrics reveal declines in revenue, operating profit, and earnings per share. Financial ratios like adjusted EPS and capital expenditures also reflect poor performance. While the company maintains a very healthy financial position with almost no debt, its declining growth and inefficient operations raise concerns about its long-term sustainability and competitiveness in the chemical and petrochemical industry. The company's asset growth is a notable positive, but it's overshadowed by other negative trends.
Tatva Chintan Pharma Chem Ltd demonstrates a mixed financial performance. The company shows excellent solvency and coverage ratios, indicating it has very little debt and strong ability to meet its interest and dividend obligations. Profitability is also a strong point, characterized by high gross profit, return on capital employed, and operating and net margins. However, the company struggles with efficiency, growth, and financial ratios. Its turnover ratios are low, suggesting challenges in utilizing assets effectively, and growth metrics reveal declines in revenue, operating profit, and earnings per share. Financial ratios like adjusted EPS and capital expenditures also reflect poor performance. While the company maintains a very healthy financial position with almost no debt, its declining growth and inefficient operations raise concerns about its long-term sustainability and competitiveness in the chemical and petrochemical industry. The company's asset growth is a notable positive, but it's overshadowed by other negative trends.
Overall Valuation Score
Markets Depth NSE
Buy Orders
Bid
Quantity
Orders
No buy depth
Total
0
0
Sell Orders
Ask
Quantity
Orders
No sell depth
Total
0
0
Markets Today NSE
High
0.00
Low
0.00
Open
0.00
Close
0.00
Prev Close
0.00
Avg Price
0.00
Volume
0
Last Traded Quantity
0
Last Traded Time
N/A
Price Movement Indicator
Today's Low: 0.00
Today's High: 0.00
P/E RATIO (TTM)
105.70
Industry Median
36.24
Small Cap Median
34.96
P/E RATIO
98.24
P/B RATIO
5.29
Industry Median
2.57
Small Cap Median
2.48
P/S RATIO
7.82
Industry Median
2.36
Small Cap Median
1.91
Others
PEG RATIO
-23.50
EV/EBITDA RATIO
40.75
The Calculations Shown Above Are Based on the Last Traded Price (LTP) of ₹1766.3 as on Aug 4, 2026.
The company's growth ratios reveal significant challenges. Declines in revenue, operating profit, and earnings per share suggest weakening performance. While asset growth is positive, it's overshadowed by other negative trends. The weighted average calculation reflects recent struggles in maintaining growth momentum. Diversification or strategic realignment may be needed to revitalize growth.
| Growth Ratios | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|---|---|
| Revenue Growth Rate | 44.67 | -2.3 | -7.08 | -2.79 | 32.11 |
| Operating Profit Growth Rate | 62.69 | -44.04 | 13.11 | -49.28 | 165.71 |
| Earnings Per Share (EPS) Growth | 66.22 | -52.55 | -36.79 | -81.19 | 636.89 |
| Asset Growth Rate | 108.89 | 15.35 | 7.91 | 2.08 | 20.1 |
| Net Income Growth Rate | 84.62 | -53.12 | -33.33 | -80 | 600 |
Revenue Growth Rate
Operating Profit Growth Rate
Earnings Per Share (EPS) Growth
Asset Growth Rate
Net Income Growth Rate
Peer Comparison empowers investors to evaluate a company against its industry peers using key financial metrics like P/E ratio, EPS, and profit margins. It helps identify whether a company is overvalued, undervalued, or performing in line with competitors. Investors can use this data to spot opportunities, assess risks, and make informed decisions. This contextual view adds depth beyond standalone company analysis.
| NO | Company Name | Health Score | P/E Ratio | Valuation | OPM | EPS | Latest Profit & Loss |
|---|---|---|---|---|---|---|---|
| 1 | J.G.Chemicals Ltd | 9.23 | 30.09 | Neutral | 82.00 | 5.47 | 69.00 |
| 2 | Platinum Industries Ltd | 8.59 | 24.00 | Neutral | 60.00 | 9.75 | 51.00 |
| 3 | Rossari Biotech Ltd | 8.46 | 19.04 | Neutral | 286.00 | 25.79 | 149.00 |
| 4 | Fineotex Chemical Ltd | 8.39 | 41.33 | Neutral | 135.00 | 0.79 | 125.00 |
| 5 | Vidhi Specialty Food Ingredients Ltd | 8.25 | 33.76 | Neutral | 78.00 | 9.84 | 49.00 |
| 6 | Bhansali Engineering Polymers Ltd | 8.25 | 16.98 | Undervalued | 216.00 | 7.25 | 180.00 |
| 7 | Styrenix Performance Materials Ltd | 8.12 | 23.93 | Neutral | 343.00 | 133.22 | 183.00 |
| 8 | Balaji Amines Ltd | 7.71 | 38.66 | Overvalued | 265.00 | 51.09 | 169.00 |
| 9 | Tatva Chintan Pharma Chem Ltd | 7.13 | 98.24 | Highly Overvalued | 93.00 | 16.71 | 42.00 |
| 10 | Neogen Chemicals Ltd | 6.69 | 191.12 | Highly Overvalued | 137.00 | 17.15 | 29.00 |
| 11 | Laxmi Organic Industries Ltd | 6.17 | 64.44 | Neutral | 171.00 | 2.86 | 79.00 |
| 12 | Yasho Industries Ltd | 6.09 | 208.11 | Neutral | 143.00 | 17.81 | 25.00 |
| 13 | Camlin Fine Sciences Ltd | 5.80 | 90.44 | Neutral | 107.00 | -1.72 | 24.00 |
| 14 | NOCIL Ltd | 5.27 | 51.35 | Neutral | 101.00 | 3.84 | 56.00 |
| 15 | Chemplast Sanmar Ltd | 4.81 | -10.98 | Neutral | 198.00 | -63.46 | -280.00 |
0 Credits RemainingUnlock Deep Technical Insights in Seconds Only with Dhanarthi AI
Overall Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Market Sentiment
Analysis Driven By 26 Technical Indicators From The 1 Hour Timeframe
Trend Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bearish
Momentum Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Volatility Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Bullish
Volume Score
Strong Bearish
Bearish
Neutral
Bullish
Strong Bullish
Neutral
Concall Report⬤24th Jan 26
Q3 FY26 Earnings Conference Call
BULLISH SENTIMENT
Quarterly Report⬤21st Jan 26
Quarterly Financial Results Q3 FY 2025–26
BULLISH SENTIMENT